Antibody Hormones In-Vitro Protein 
Camargo
NOVEMBER 29, 2021
Recombinant therapeutic proteins. Fusion proteins. Monoclonal antibodies (mAbs). In vitro binding assays and functional tests might be required to identify the test material which is pharmacologically active , and a potency assay is required due to the complexity and heterogeneity of biologics. Growth factors.
The Pharma Data
AUGUST 6, 2020
Safety for the Tecentriq combination appeared to be consistent with the known safety profile of the individual medicines, and no new safety signals were identified. Roche’s Chief Medical Officer and Head of Global Product Development. This includes studies evaluating Tecentriq both alone and in combination with other medicines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
APRIL 27, 2021
The advisory committee provides the FDA with independent opinions and recommendations from outside medical experts, though the recommendations are not binding. The FDA has not announced when it will make its final decision for Tecentriq in this indication. Roche’s Chief Medical Officer and Head of Global Product Development.
Drug Discovery World
APRIL 11, 2024
The company reported that these data further support the combination of nab-sirolimus with endocrine therapy for hormone-driven cancers, as is currently being investigated in patients with advanced or recurrent endometrioid endometrial cancer in a Phase II study. And thanks to the city of San Diego for its hospitality.”
The Pharma Data
SEPTEMBER 16, 2020
New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Join this event on Roche’s LinkedIn page here. Roche highlights featured at ESMO Virtual Congress 2020.
The Pharma Data
SEPTEMBER 19, 2020
Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapy. Roche’s Chief Medical Officer and Head of Global Product Development. from 41.1% (95% CI: 33.6–48.9)
Pfizer
JANUARY 27, 2023
Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern.
Expert insights. Personalized for you.
180 
Let's personalize your content